Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18411323 | PYRAZOLO[1,5-a]PYRIDO[4,3-e]PYRIMIDINE-2-CARBOXYLIC ACIDS AS CK2 INHIBITORS | January 2024 | May 2024 | Allow | 4 | 0 | 1 | No | No |
| 18408940 | PYRIDO[4,3-E][1,2,3]TRIAZOLO[1,5-A]PYRIMIDINE AS CK2 INHIBITORS | January 2024 | April 2024 | Allow | 3 | 0 | 1 | No | No |
| 18404721 | IMIDAZO[1,5-a]PYRIDO[4,3-e]PYRIMIDINES AS CK2 INHIBITORS | January 2024 | April 2024 | Allow | 4 | 0 | 1 | No | No |
| 18535108 | MATERIAL AND METHOD FOR TREATING CANCER | December 2023 | September 2024 | Allow | 9 | 1 | 1 | No | No |
| 18383135 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | October 2023 | November 2025 | Allow | 25 | 0 | 0 | Yes | No |
| 18264939 | SYNTHESIS OF TIGILANOL TIGLATE AND ANALOGS THEREOF | August 2023 | December 2025 | Allow | 28 | 0 | 0 | No | No |
| 18035491 | SMALL MOLECULE COMPOUND AND USE AND COMPOSITION THEREOF | June 2023 | October 2025 | Allow | 29 | 0 | 0 | Yes | No |
| 18257976 | MACROCYCLIC BRANCHED 3-FLUORO-BUT-3-ENAMIDES AS INHIBITORS OF MCL-1 | June 2023 | October 2025 | Allow | 28 | 0 | 0 | No | No |
| 18265425 | PYRIDINYLPYRAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | June 2023 | October 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 18265023 | Heterocyclic Derivatives as P2X7 Receptor Antagonists | June 2023 | October 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 18253572 | MALT-1 MODULATORS | May 2023 | September 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 18138357 | PROCESS-SCALE SYNTHESIS OF UROLITHIN A | April 2023 | February 2025 | Allow | 22 | 1 | 1 | No | No |
| 18298256 | CELL SIGNAL DETECTION AND MODULATION IN DISEASE | April 2023 | May 2024 | Abandon | 13 | 0 | 1 | No | No |
| 18296215 | Salt Forms and Solvates of Mcl-1 Antagonists | April 2023 | March 2025 | Allow | 23 | 0 | 0 | Yes | No |
| 18295476 | Compositions And Methods For The Treatment Of Alopecia | April 2023 | June 2025 | Allow | 26 | 3 | 1 | Yes | No |
| 18187866 | COMPOSITIONS AND METHODS FOR TREATING CASTRATION-RESISTANT PROSTATE CANCER | March 2023 | January 2025 | Abandon | 22 | 2 | 1 | No | No |
| 18186816 | COMBINATION THERAPY FOR TREATING CANCER | March 2023 | July 2025 | Allow | 28 | 3 | 1 | Yes | No |
| 18182620 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | March 2023 | November 2025 | Allow | 32 | 0 | 1 | No | No |
| 18115955 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | March 2023 | September 2024 | Abandon | 18 | 1 | 1 | No | No |
| 18005713 | HERBICIDAL COMPOUNDS | January 2023 | September 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 18004628 | SALTS AND FORMS OF A WEE1 INHIBITOR | January 2023 | December 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 17988062 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | November 2022 | March 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17982487 | ISOTOPICALLY ENRICHED 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDE) AND STEREOISOMERS THEREOF | November 2022 | June 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17997375 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | October 2022 | March 2026 | Abandon | 40 | 1 | 0 | No | No |
| 18048719 | OMEGA MURICHOLIC ACID AS A PREGNANE X RECEPTOR LIGAND FOR TREATING HEPATO-INTESTINAL DISEASES | October 2022 | June 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17917593 | NEW ANTI-MALARIAL AGENTS | October 2022 | September 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17937977 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE | October 2022 | June 2025 | Allow | 32 | 3 | 1 | Yes | No |
| 17935961 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA 1 PAM | September 2022 | December 2024 | Allow | 26 | 1 | 1 | No | No |
| 17948251 | INHIBITION OF PROTEIN AMYLOID AGGREGATION USING FLUORINATED BENZENESULFONAMIDES | September 2022 | December 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17899814 | Synthesis method of lactide by confinement effect catalysis of crystalline porous polymer material | August 2022 | January 2024 | Allow | 17 | 1 | 0 | No | No |
| 17862962 | PROANGIOGENIC PROTEIN COCKTAILS DELIVERED IN CUSTOM BIOMATERIALS TO REVASCULARIZE ISCHEMIC TISSUE | July 2022 | May 2024 | Allow | 22 | 1 | 0 | No | No |
| 17791834 | Modified Thioxanthone Photoinitiators | July 2022 | September 2025 | Allow | 39 | 0 | 0 | Yes | No |
| 17788680 | GALECTIN-3 INHIBITING C-GLYCOSIDE KETONES, ETHERS, AND ALCOHOLS | June 2022 | April 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17806695 | INTRATUMORAL ADMINISTRATION OF ASCORBIC ACID AND QUINONE COMPOUNDS FOR TUMOR TREATMENT | June 2022 | October 2025 | Abandon | 40 | 2 | 0 | No | No |
| 17836871 | CONTROLLED-DELIVERY CROMAKALIM PRODRUGS | June 2022 | June 2025 | Allow | 37 | 0 | 0 | Yes | No |
| 17781201 | BIARYL COMPOUND AS PAN-RAF KINASE INHIBITOR | May 2022 | July 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17730565 | AZA-HETEROCYCLYL CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | April 2022 | September 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17771114 | BICYCLIC COMPOUND AND USE THEREOF | April 2022 | March 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17766400 | HETEROCYCLIC COMPOUND | April 2022 | March 2025 | Allow | 35 | 0 | 0 | No | No |
| 17629530 | ERGOTHIONEINE, S-METHYL-ERGOTHIONEINE, AND USES THEREOF | January 2022 | February 2026 | Allow | 49 | 2 | 0 | Yes | No |
| 17626777 | CRYSTALLINE FORMS OF SOMATOSTATIN MODULATORS | January 2022 | January 2026 | Allow | 48 | 2 | 1 | Yes | No |
| 17644486 | PYRIDYLPYRIDONE COMPOUNDS | December 2021 | March 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17546204 | MATERIAL AND METHOD FOR TREATING CANCER | December 2021 | February 2025 | Allow | 38 | 2 | 0 | Yes | Yes |
| 17615008 | Composition for Prevention, Amelioration, or Treatment of Cancer | November 2021 | June 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17512326 | TREATMENT OF CANCER AND INHIBITION OF METASTASIS | October 2021 | December 2025 | Allow | 50 | 2 | 0 | No | No |
| 17594577 | COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS | October 2021 | April 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17604322 | PROCESS FOR PREPARATION OF AXITINIB | October 2021 | September 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17498256 | Combinations For Treatment Of NASH/NAFLD And Related Diseases | October 2021 | November 2024 | Allow | 37 | 0 | 0 | Yes | No |
| 17493397 | STABLE PARENTERAL DOSAGE FORM OF PYRAZOLONE DERIVATIVE | October 2021 | May 2024 | Abandon | 31 | 0 | 1 | No | No |
| 17440705 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | September 2021 | March 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17422644 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | July 2021 | June 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17419833 | INHIBITORS OF CGAS ACTIVITY AS THERAPEUTIC AGENTS | June 2021 | March 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17419997 | IL-17A INHIBITORS | June 2021 | December 2024 | Allow | 42 | 0 | 1 | Yes | No |
| 17418034 | DOMPERIDONE COMPOSITIONS AND METHODS FOR TREATING DEPRESSION | June 2021 | April 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17416682 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | June 2021 | November 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 17414478 | PYRIDYLOXY CARBOXYLATE DERIVATIVE, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | June 2021 | June 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17311212 | QUINOLINONE AND BENZOXAZINE DERIVATIVES AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | June 2021 | October 2024 | Allow | 40 | 0 | 1 | Yes | No |
| 17337077 | FORMULATIONS FOR PERSONALIZED METHODS OF TREATMENT | June 2021 | September 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17291497 | DOMPERIDONE ANTINEURODEGENERATIVE COMBINATIONS AND USE | May 2021 | May 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17284429 | SIMPLE PREPARATION METHOD FOR VABORBACTAM | April 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17225968 | FORMULATION FOR PAIN MANAGEMENT | April 2021 | October 2024 | Allow | 42 | 1 | 1 | No | No |
| 17216357 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | March 2021 | January 2026 | Allow | 58 | 3 | 0 | Yes | Yes |
| 17279644 | COMPOSITION AND USE FOR THE TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS | March 2021 | January 2026 | Abandon | 57 | 2 | 1 | No | No |
| 17274379 | METHOD OF PREPARING ACRYLONITRILE DIMER | March 2021 | February 2025 | Allow | 47 | 3 | 0 | Yes | No |
| 17274274 | COMPOSITION, COMPRISING THIAMINE DERIVATIVE, FOR PREVENTION OR TREATMENT OF HYPERCORTISOLEMIA | March 2021 | June 2025 | Allow | 51 | 3 | 0 | No | No |
| 17191310 | CRYSTALLINE FORMS OF 6-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)NICOTINAMIDE | March 2021 | November 2023 | Allow | 33 | 0 | 0 | No | No |
| 17271883 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | February 2021 | July 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17184776 | SIGMA RECEPTOR BINDERS | February 2021 | November 2025 | Abandon | 57 | 3 | 1 | Yes | No |
| 17267513 | NLRP3 MODULATORS | February 2021 | September 2024 | Allow | 43 | 1 | 1 | No | No |
| 17261267 | Thioxanthone Derivatives, Composition Comprising the Same and Pattern Forming Method Comprising Said Composition | January 2021 | April 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17260602 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING INFLAMMATORY BOWEL DISEASE | January 2021 | June 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17260682 | METHODS FOR PURIFYING ISAVUCONAZONIUM SULFATE | January 2021 | May 2025 | Allow | 52 | 2 | 1 | No | No |
| 17260484 | OPIOID HAPTENS, CONJUGATES, VACCINES, AND METHODS OF GENERATING ANTIBODIES | January 2021 | May 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17259357 | T-TYPE CALCIUM CHANNEL BLOCKER | January 2021 | October 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17259370 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | January 2021 | September 2024 | Allow | 44 | 1 | 1 | Yes | No |
| 17258040 | CRYSTALLINE SALTS OF 5-METHYL-(6S)-TETRAHYDROFOLIC ACID AND AMINO ETHYL ESTERS | January 2021 | October 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 16955510 | QUINAZOLINE DERIVATIVE AND USE THEREOF | December 2020 | April 2025 | Abandon | 58 | 1 | 1 | No | No |
| 17101182 | NEAR-INFRARED ABSORBING DYE, OPTICAL FILTER, AND IMAGING DEVICE | November 2020 | August 2024 | Allow | 45 | 1 | 1 | No | No |
| 17050956 | HIGH CANNABIDIOL CONTAINING CANNABIS CHEMOTYPES | October 2020 | May 2024 | Abandon | 43 | 0 | 1 | No | No |
| 16960819 | PHOSPHOR(N)AMIDATACETAL AND PHOSPH(ON)ATALCETAL COMPOUNDS | October 2020 | July 2024 | Allow | 48 | 1 | 1 | No | No |
| 17043763 | COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASE | September 2020 | July 2024 | Abandon | 45 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MCANANY, JOHN D.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MCANANY, JOHN D works in Art Unit 1625 and has examined 40 patent applications in our dataset. With an allowance rate of 60.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.
Examiner MCANANY, JOHN D's allowance rate of 60.0% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MCANANY, JOHN D receive 1.15 office actions before reaching final disposition. This places the examiner in the 13% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by MCANANY, JOHN D is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +59.3% benefit to allowance rate for applications examined by MCANANY, JOHN D. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 71% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 80.0% of cases where such amendments are filed. This entry rate is in the 96% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.